New test aims to match lung cancer patients with best therapy

NCT ID NCT07250477

Recruiting now Disease control Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether using a proteomic test (PROphet CB) and a toxicity assessment (CARG-TT) to guide first-line treatment can improve 12-month survival in people with advanced non-small cell lung cancer. About 56 participants will be randomly assigned to receive either standard care or a personalized treatment plan based on these tests. The goal is to see if this tailored approach leads to better outcomes and fewer severe side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Immune checkpoint inhibitor (ICI) with or without chemotherapy, guided by a proteomic test (PROphet CB) and a toxicity risk assessment (CARG-TT)
What this could lead to: If successful, this approach could help doctors choose the most effective first-line treatment for each patient with advanced lung cancer, potentially improving survival and reducing side effects.
What could go wrong: This is a small, early-phase (phase 2) trial with only 56 participants, so results may not apply to all patients. The proteomic test is new and unproven, and the treatment may not improve outcomes or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER METASTATIC NON-SMALL CELL LUNG CANCER STAGE IIIC NON-SMALL CELL LUNG CANCER STAGE IV NON-SMALL CELL LUNG CANCER UNRESECTABLE

Contacts and locations

Locations

University of California Davis Comprehensive Cancer Center
RECRUITING

Sacramento, California, 95817, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.